- MDS (myelodysplastic syndromes) may be treated by immuno-suppressive therapies such as anti-thymocyte globulin.
- Patient responses to these therapies is variable. Hence methods are needed to better predict responses to immuno-suppressive therapy.
- A Moffitt researcher has discovered biomarkers for predicting response of MDS patients to therapy with anti-thymocyte globulin.
FEATURES AND BENEFITS
- The method is based on T-cell surface markers that can be assayed by routine flow cytometry methods.
- The markers are well known and can be measured with standard reagents.
- Simple ratios of certain T-cell populations predict which patients will respond to therapy with anti-thymocyte globulin.
STAGE OF DEVELOPMENT
Retrospective proof of concept. Clinical trials are under way.
- J.X. Zou et al. (2009) Leukemia 23:1288-1296.
- US Patent Pending
Haskell Adler PhD MBA CLP
Senior Licensing Manager
Registered Patent Agent